- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798156
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (R-Pola-Glo)
A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Björn Chapuy, Univ.-Prof. Dr. med.
- Phone Number: +49 30 450 613423
- Email: bjoern.chapuy@charite.de
Study Contact Backup
- Name: Richard Greil, Univ. Prof. Dr. med.
- Email: r.greil@salk.at
Study Locations
-
-
-
Linz, Austria
- Not yet recruiting
- Kepler Universitätsklinikum
-
Contact:
- Clemens Schmitt
-
Linz, Austria
- Recruiting
- Ordensklinikum Linz - Barmherzige Schwestern
-
Contact:
- Manuel Orlinger
-
Linz, Austria
- Not yet recruiting
- Ordensklinikum Linz - Elisabethinen
-
Contact:
- Natalia Rotter
-
Salzburg, Austria
- Recruiting
- Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
-
Contact:
- Richard Greil, Prof. Dr. med.
-
St. Pölten, Austria
- Recruiting
- Univ. Klinikum St. Pölten
-
Contact:
- Petra Pichler
-
Wien, Austria
- Recruiting
- AKH Meduni Wien
-
Contact:
- Phillip Staber
-
Wien, Austria
- Recruiting
- Hanusch Krankenhaus
-
Contact:
- Michael Panny
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charité - Universitätsmedizin Berlin
-
Contact:
- Björn Chapuy, Prof. Dr.
-
Berlin, Germany
- Not yet recruiting
- Helios Klinikum Berlin-Buch
-
Contact:
- Anna Ossami Saidy, Dr.
-
Bochum, Germany
- Recruiting
- Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum
-
Contact:
- Roland Schroers, Prof. Dr.
-
Chemnitz, Germany
- Recruiting
- Klinikum Chemnitz
-
Contact:
- Mathias Hänel, PD Dr. med. habil.
-
Erlangen, Germany
- Not yet recruiting
- Universitätsklinikum Erlangen
-
Contact:
- Fabian Müller, PD. Dr. med
-
Essen, Germany
- Recruiting
- Ev. Klinikum Essen-Mitte
-
Contact:
- Peter Reimer, Prof. Dr.
-
Halle, Germany
- Not yet recruiting
- Universitätsklinikum Halle
-
Contact:
- Thomas Weber, Dr.
-
Jena, Germany
- Not yet recruiting
- University Hospital Jena
-
Contact:
- Ulf Schnetzke, PD Dr. med.
-
Kiel, Germany
- Not yet recruiting
- Universitätsklinikum Schleswig-Holstein Campus Kiel
-
Contact:
- Christiane Pott, Prof. Dr. med.
-
Leipzig, Germany, 04103
- Recruiting
- Universitatsklinikum Leipzig
-
Contact:
- Simone Heyn, Dr. med.
-
Ludwigshafen, Germany, 67063
- Recruiting
- Klinikum Ludwigshafen
-
Contact:
- Martin Hoffmann, Dr.
-
München, Germany
- Not yet recruiting
- TU München (rechts des Isar)
-
Contact:
- Anna Lena Illert, Prof. Dr med.
-
Münster, Germany, 48149
- Recruiting
- Unversitätsklinikum Münster
-
Contact:
- Andrea Kerkhoff, MD
-
Offenburg, Germany
- Not yet recruiting
- Ortenauklinikum Offenburg-Kehl
-
Contact:
- Carsten Schwänen, PD Dr.
-
Regensburg, Germany
- Not yet recruiting
- Universitätsklinikum Regensburg
-
Contact:
- Stephanie Mayer, Dr.
-
Reutlingen, Germany
- Recruiting
- Kreiskliniken Reutlingen
-
Contact:
- Angela Huster, Dr.
-
Würzburg, Germany
- Not yet recruiting
- Universitatsklinikum Wurzburg
-
Contact:
- Johannes Düll, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient has provided written informed consent and is able and willing to comply with the study protocol and protocol mandated hospitalizations according to ICH and local regulations.
- Patient is above 60 years of age
- Patient is not eligible for a fully dosed R-CHOP
- Patient has histologically confirmed aggressive B-cell lymphoma.
- Patient has at least one measurable FDG PET-positive lymphoma manifestation; defined as lesional maximum FDG uptake higher than the maximum FDG uptake in unaffected liver parenchyma as measured in a reference volume-of-interest with >10 mL
- Baseline biopsy material is available for central review.
Female patients considered as women of childbearing potential (WOCBP, see section 5.2.7 for definition) and male patients with female partners considered as WOCBP must:
- agree to either remain completely abstinent (refrain from heterosexual intercourse) or to use at least one effective contraceptive methods that results in a failure rate of < 1% per year
- refrain from donating ova (female patients) or donating sperm (male patients)
- in case of male patients with pregnant female partners, remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom to avoid exposing the embryo.
- Patient did not receive any prior lymphoma therapy.
- Patient has an ECOG performance status of ≤ 2.
- Patient has with treatment a life expectancy (in the opinion of the investigator) of at least 12 weeks.
- Patient has adequate liver function
- Patient as adequate hematological function
- Patient has adequate renal function
Patients has negative serologic and/or polymerase chain reaction (PCR) test results for:
- Acute or chronic hepatitis B (HBV) infection.
- Hepatis C virus (HCV) and human immunodeficiency virus (HIV)
- Patient has no active SARS-CoV-2 infection.
Exclusion Criteria:
Medical conditions:
- Patient with chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) (including CD20+ ALL), lymphoblastic lymphoma, Richter's transformation, Burkitt lymphoma.
- Patient ≤ 60 years
- Patient with known active infection, or reactivation of a latent infection, whether bacterial (e.g., tuberculosis), viral (including, but not limited to severe pneumonia, COVID-19, Epstein-Barr virus [EBV], cytomegalovirus [CMV], hepatitis B, hepatitis C, and HIV], fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks prior to study enrollment.
- Patient with current > Grade 1 peripheral neuropathy.
- Patient with history of confirmed progressive multifocal leukoencephalopathy (PML).
- Patient with history of leptomeningeal disease.
- Patient with current or history of CNS lymphoma.
- Patient with current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease with exceptions.
- Patient with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence), with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%), such as adequately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- Patient with significant or extensive history of cardiovascular disease (such as New York Heart Association (NYHA) Class ≥ II cardiac disease, congestive heart failure, myocardial infarction or cerebrovascular accident within the past 3 months, unstable arrhythmias, or unstable angina or history of multiple cardiovascular events) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
- Patient with active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (see addendum for a more comprehensive list of autoimmune diseases and immune deficiencies), with exceptions.
- Patient with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
Patient with history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic.
Prior/Concomitant Therapy:
- Patient received treatment with any other standard anti-cancer radiotherapy/chemotherapy including investigational therapy (defined as treatment for which there is currently no regulatory authority approved indication) within 4 weeks or five times the elimination half-life of the product, whichever is longer, prior to study enrollment.
- Patient with prior solid organ transplantation.
- Patient with prior allogeneic stem cell transplantation.
- Patient with prior treatment with targeted therapies (e.g., tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to study enrollment.
- Patient with toxicities from prior anti-cancer therapy including immunotherapy that did not resolve to ≤ Grade 1 except for alopecia, endocrinopathy managed with replacement therapy and stable vitiligo.
- Patient with any history of immune related ≥ Grade 3 AE except for endocrinopathy managed with replacement therapy.
- Patient with ongoing corticosteroid use 25 mg/day of prednisone or equivalent within 4 weeks prior and during study treatment.
- Patient with treatment with systemic immunosuppressive medication (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions.
Patient who received administration of a live, attenuated vaccine within 4 weeks prior to study enrollment infusion or anticipation that such a live, attenuated vaccine will be required during the study or within 5 months after the last dose of study treatment.
Other Exclusions:
- Patient with history of illicit drug or alcohol abuse within 12 months prior to screening, in the Investigator's judgment.
- Patient with history of severe allergic anaphylactic reactions to chimeric or humanized monoclonal antibodies or recombinant antibody-related fusion proteins.
- Patient with known hypersensitivity to Chinese hamster ovary (CHO) cell products or to any component of the rituximab, obinutuzumab, polatuzumab vedotin and/or glofitamab formulation and/or to the contrast agents used in the study.
- Female patient is pregnant or breast feeding. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
- Patients who are dependent on the sponsor, the investigator or the trial site.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: chemolight R-Pola-Glo treatment
|
Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1 year progression-free survival (PFS) rate
Time Frame: 12 months
|
defined as the time from the day of inclusion until disease progression (PD) or relapse after complete remission (CR), or death due to any cause, whichever occurs first
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival (EFS)
Time Frame: 54 months
|
defined as the time from the day of inclusion until progressive disease or relapse after complete remission, initiation of subsequent systemic antilymphoma treatment, radiation of single PET-CT positive lesions or death due to any cause, whichever occurs first.
|
54 months
|
Overall survival (OS)
Time Frame: 54 months
|
defined as the time from the day of inclusion until death due to any cause
|
54 months
|
Response rate at different timepoints
Time Frame: 6 weeks, 18 weeks, 36 weeks
|
Response rates after 2 cycles (during target dose phase), 6 cycles (end of target dose phase before start of consolidation phase) and 12 cycles (end of treatment following completion of consolidation phase).
i.e., complete remission (CR) rate, partial remission (PR) rate, overall remission rate (ORR: CR+PR), stable disease (SD) rate and progressive disease (PD) rate
|
6 weeks, 18 weeks, 36 weeks
|
Relapse rate
Time Frame: 54 months
|
defined as the number of patients with relapse, divided by the number of patients achieving C
|
54 months
|
Conversion rate of PR to CR
Time Frame: 54 months
|
defined as the number of patients achieving mCR at the end of study treatment (including consolidation phase) divided by the number of patients achieving PR after end of target dose phase (before start of consolidation phase)
|
54 months
|
Duration of response (DoR)
Time Frame: 54 months
|
defined as the time from documentation of CR until relapse or lymphoma associated death without documented relapse
|
54 months
|
Rate and type of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 54 months
|
54 months
|
|
Rate of secondary malignancies
Time Frame: 54 months
|
defined as the number of patients with secondary malignancies divided by the number of analyzable patients
|
54 months
|
Treatment-related death rate
Time Frame: 54 months
|
defined as the number of treatment related deaths during therapy or up to 2 months after the end of study treatment, but before the start of further treatment, divided by the number of analyzable patients
|
54 months
|
Protocol adherence
Time Frame: 54 months
|
number and duration of R-Pola-Glo cycles, number and duration of glofitamab maintenance, cumulative and relative doses of rituximab, glofitamab and polatuzumab.
|
54 months
|
Patient-reported outcomes for quality of life (QoL): EORTC QLQ-C30
Time Frame: 54 months
|
measured by EORTC QLQ-C30 (a 30-item questionnaire developed by the European Organisation for Research and Treatment of Cancer).
All of the scales and single-item measures range in score from 0 to 100.
A high scale score represents a higher response level.
|
54 months
|
Patient-reported outcomes for quality of life (QoL): FACT-Lym
Time Frame: 54 months
|
measured by FACT-Lym (Functional Assessment of Cancer Therapy - Lymphoma; scores from 0 - 4; The higher the score, the better the QOL)
|
54 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of minimal residual disease (MRD)-negative patients after end of target phase and at end of treatment
Time Frame: 54 months
|
54 months
|
Duration of molecular remission for MRD negative patients
Time Frame: 54 months
|
54 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Salah-Eddin Al-Batran, Prof. Dr., Institut fuer Klinische Krebsforschung IKF GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immunoconjugates
- Rituximab
- Obinutuzumab
- Polatuzumab vedotin
Other Study ID Numbers
- R-Pola-Glo
- 2022-003398-51 (EudraCT Number)
- GLA 2022-10 (Other Identifier: GLA)
- NHL-16 (Other Identifier: AGMT)
- ML44400 (Other Grant/Funding Number: Roche)
- IKF-t062 (Other Identifier: Institut für klinische Krebsforschung IKF GmbH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Glofitamab
-
The Lymphoma Academic Research OrganisationActive, not recruitingRefractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell LymphomaFrance
-
University Health Network, TorontoNot yet recruitingDiffuse Large B Cell Lymphoma (DLBCL)Canada
-
PfizerHoffmann-La RocheRecruitingDiffuse Large B-Cell LymphomaTaiwan, United States, Japan
-
Hoffmann-La RocheCompleted
-
French Innovative Leukemia OrganisationHoffmann-La RocheNot yet recruiting
-
Hoffmann-La RocheRecruitingLymphoma, Non-HodgkinUnited States, Denmark, Italy, France, Australia, United Kingdom
-
Reid Merryman, MDGenentech, Inc.RecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin LymphomaUnited States
-
Hoffmann-La RocheRecruitingNon-Hodgkin LymphomaUnited States, Israel, Italy, Spain, United Kingdom
-
Hoffmann-La RocheRecruitingNon-Hodgkin's LymphomaBelgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
-
Abramson Cancer Center at Penn MedicineGenentech, Inc.RecruitingDLBCL - Diffuse Large B Cell Lymphoma | Large B-cell LymphomaUnited States